Clinical Trial

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Protocol Amendment History 2 changes
minor Completion pushed: 2038-01-26 -> 2042-06-01 2026-05-09
minor Completion pushed: 2037-10-30 -> 2038-01-26 2026-04-14
Trial Details
NCT Number NCT05201781
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 295 participants
Start Date 2022-03-09
Primary Completion 2037-07-29 (estimated)
Study Completion 2042-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-06